Deep Diamond India Ltd

Deep Health AI India Ltd has announced the closure of its trading window for dealing in equity shares. This closure is effective from the trading hours of July 01, 2026, and will continue until 48 hours after the declaration of the Un-Audited Financial Results for the Quarter ended June 30, 2026. The measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations. All designated persons and their immediate relatives are prohibited from trading in the company's securities during this period. The date for the Board meeting to approve the financial results will be communicated separately.

Deep Health AI India Ltd has acquired a 6.37% stake in Leapfrog Engineering Services Ltd. for ₹19,92,01,800. The acquisition involved 90,30,000 equity shares at ₹22.06 each. Leapfrog Engineering Services Ltd. is an integrated engineering services company specializing in EPCC services for various industries including Oil and Gas, Food Processing, Pharma, and Metals. The company reported a turnover of ₹13,466.24 lakhs as of March 31, 2025. This acquisition is considered a routine investment and does not involve related party transactions. No governmental or regulatory approvals were required, and the acquisition was completed on June 24, 2026.

Deep Health AI India Ltd. has announced the approval of its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The decision was made during a board meeting held on May 29, 2026. Additionally, M/s. Valawat & Associates Chartered Accountants were appointed as the Internal Auditor for the financial year 2026-2027.

Deep Health AI India Ltd's board approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The board also approved the appointment of M/s. Valawat & Associates as Internal Auditor for the financial year 2026-2027. The meeting, held via video conferencing, took place on May 29, 2026, in Udaipur, Rajasthan. This follows earlier intimations regarding the board meeting and deferred agenda item approval.

Deep Health AI India Ltd. reports full utilization of Rights Issue proceeds as of March 31, 2026, thus concluding the applicability of Regulation 32 filings. A statement of deviation and variation for the quarter and year ended March 31, 2026, reviewed by the Audit Committee on May 29, 2026, along with a Utilisation Certificate from M/s VRSK & Co. LLP, is enclosed. The rights issue raised ₹39,97,76,000 on October 6, 2025. Deviations included investment in equity shares and excessive issue expenses, approved by shareholders on January 22, 2026.

The Board of Directors of Shamrock Industrial Company Limited has deferred the consideration and approval of the Audited Standalone and Consolidated Financial Results for the Financial Year ended March 31, 2026, due to paucity of time and the need for further clarifications from the Management. The decision was made during a board meeting held on May 27, 2026, which commenced at 02.00 P.M and concluded at 09.50 P.M. The matter will now be taken up for consideration on Friday, May 29, 2026.

Deep Health AI India Ltd (formerly Deep Diamond India Limited) has scheduled a Board of Directors meeting on May 27, 2026, to consider and approve the audited standalone and consolidated financial results for the year ended March 31, 2026. The trading window for dealing in the company's shares has been closed from April 1, 2026, and will remain closed until 48 hours after the declaration of the results.

Deep Health AI India Ltd's board approved raising funds up to ₹25 crores through a rights issue of fully paid-up equity shares to existing shareholders. A Rights Issue Committee has been formed to decide on the terms, including issue size, ratio, price, and record date. The board also approved the Draft Letter of Offer and authorized the application for in-principal approval for the rights issue.

Deep Health AI India Ltd. has scheduled a Board of Directors meeting for May 4, 2026, to discuss and approve a proposal for raising funds. The primary agenda includes the consideration and approval of issuing Equity Shares on a Rights basis to existing shareholders, in accordance with relevant Companies Act and SEBI regulations. Furthermore, the company has informed that the trading window for its directors, officers, and designated employees has been closed since April 1, 2026. This closure will remain in effect until 48 hours after the declaration of the Audited Financial Results for the quarter and financial year ended March 31, 2026, to comply with SEBI (Prohibition of Insider Trading) Regulations, 2015.

Deep Health AI India Ltd (formerly known as Deep Diamond India Limited) announced the resignation of Mr. Kailash Chandra as an Independent Director, effective from the close of business hours on April 03, 2026. The company provided the required details in terms of Regulation 30 - Part A of Para A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. Mr. Chandra is no longer associated with any other company and has provided a detailed reason for his resignation in the enclosed letter.